GlobeNewswire Inc.··Ataibeckley Inc.AtaiBeckley's BPL-003 Shows Durable Antidepressant Benefits in Treatment-Resistant Depression
AtaiBeckley's BPL-003 nasal spray demonstrates rapid and sustained antidepressant effects in treatment-resistant depression Phase 2a trial, advancing toward Phase 3 launch in Q2 2026.
ATAIPhase 3 clinical trialtreatment-resistant depression